PLX

Protalix BioTherapeutics, Inc.

PLX · CIK 1006281 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$53M
20172024
Net Income$3M
20172024
Operating CF$9M
20172024
Free Cash Flow$7M
20172024

Income Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Revenue$0.1B$0.1B$0.0B$0.0B$0.1B$0.1B—$0.0B
Cost of Revenue$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Gross Profit———————$0.0B
R&D Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
SG&A Expense$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Operating Income$0.0B$0.0B$-0.0B$-0.0B$0.0B$0.0B$-0.0B$-0.0B
Net Income$0.0B$0.0B$-0.0B$-0.0B$-0.0B$0.0B$-0.0B$-0.1B
EPS (Basic)$0.04$0.12$-0.31$-0.62————
EPS (Diluted)$0.04$0.09$-0.31$-0.62————

Balance Sheet

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Total Assets$0.1B$0.1B$0.1B$0.1B$0.1B$0.0B$0.1B$0.1B
Current Assets$0.1B$0.1B$0.0B$0.1B$0.1B$0.0B$0.1B$0.1B
Cash & Equivalents$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.1B
Total Liabilities$0.0B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B$0.1B
Current Liabilities$0.0B$0.0B$0.0B$0.0B$0.1B$0.0B$0.0B$0.0B
Stockholders' Equity$0.0B$0.0B$-0.0B$-0.0B$-0.0B$-0.1B$-0.1B$-0.0B

Cash Flow Statement

MetricFY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕FY 2017↕
Operating Cash Flow$0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Investing Cash Flow$0.0B$-0.0B$-0.0B$0.0B$-0.0B$-0.0B$-0.0B$-0.0B
Capital Expenditures$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$-0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$-0.0B$-0.0B
← Companies